Even though the comparison of NPC markers did not reveal any neuroectodermal acquisition defects as previously described in HD and AD NPCs [16,29,30,31], the transcriptome profile of mutant NPCs indicates differences in 32 factors (26 upregulated and 6 downregulated) (Figure 2B, Supplementary Table S5) including the neurogenic molecules, NeuroD1, NeuroG1, NeuroG2, EDN1, CHRDL1, ERBB3, EFNA2, SOX8, LGI4, NTRK1, ISLR2, FOXD3, DCDC2, FOXN4, and NTN5. This evidence concerns the gene CHRDL1 and Huntington disease.